Hosted on MSN15m
J&J’s fully subcutaneous Tremfya shows 27.6% clinical remission in UC
Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...
manilatimes12h
Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal ...